Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2 studies found for:    weill | Open Studies | "Breast Neoplasms, Male"
Show Display Options
Rank Status Study
1 Recruiting Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Conditions: Estrogen Receptor Positive;   HER2/Neu Negative;   Male Breast Carcinoma;   Progesterone Receptor Positive;   Recurrent Breast Carcinoma;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Entinostat;   Drug: Exemestane;   Drug: Goserelin Acetate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Other: Placebo;   Other: Quality-of-Life Assessment
2 Recruiting S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo

Indicates status has not been verified in more than two years